North America Peptide Therapeutics Market Size, Share & Industry Trends Analysis Report By Type (Innovative and Generic), By Route of Administration, By Synthesis Technology, By Type of Manufacturers, By Application, By Country and Growth Forecast, 2022 - 2028
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the North America Peptide Therapeutics Market
Market Report Description
The North America Peptide Therapeutics Market would witness market growth of 5.2% CAGR during the forecast period (2022-2028).
Peptides can also benefit the skin of a person. The skin barrier source can be identified as the line of defense of a body that protects the skin from UV rays, pollution, bacteria, and other toxins. Excessive exfoliation, contact with cigarette smoke as well as other pollution particles, and even lack of sleep can all harm the skin barrier. Peptides help in the formation of a robust barrier. Collagen can help to fill up the skin and lips. Fine lines and wrinkles will be less evident when the skin is firmer and plumper. Peptides are also found in elastin fibers, which are another form of protein.
When it comes to peptide stability and half-life, another technique to consider is lipidation. Because the lipid chain non-covalently interacts with serum albumin to raise the molecular weight, attaching a lipid chain to the peptide head group inhibits proteolytic attack and thereby reduces renal filtration. Because of its affinity for human serum albumin, studies on detemir, a lipidated analog of insulin, indicated that it had a longer action. Furthermore, lipidation has been demonstrated to improve peptide interaction with cell membranes, enabling them to be absorbed into the cell more readily than peptides lacking the lipid component.
The adoption of novel drugs for the treatment of various diseases is increasing in this region. According to the National Library of Medicines, the Food and Drug Administration (FDA) approved 53 medications in 2020, bringing the total number of approved entities (new chemical biologics and entities) to 228 in the last five years (2016–2020). Six peptides and oligonucleotides are among the 53 medications that were approved in 2020. In this context, 23 TIDES have been authorized in the last five years. These figures bolster the TIDES market, which contributes to approximately 10% of the overall in terms of number of medications.
Moreover, peptides and proteins have appeared with a slew of new uses in the diagnostic and therapeutic sectors as a result of major advances in biologics and biopharmaceuticals over the past few years. According to current estimates of the organization, the market for peptide and protein therapeutics accounts for around 10% of the total pharmaceutical market and is expected to grow even more in the future. Since the early 1980s, the US Food and Drug Administration has approved 239 therapeutic proteins and peptides for clinical use. With the increasing adoption of peptides along with the upcoming developments in the sector, the growth of the peptide therapeutics market is increasing.
The US market dominated the North America Peptide Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $16,967.9 million by 2028. The Canada market is anticipated to grow at a CAGR of 7.6% during (2022 - 2028). Additionally, The Mexico market would showcase a CAGR of 6.6% during (2022 - 2028).
Based on Type, the market is segmented into Innovative and Generic. Based on Route of Administration, the market is segmented into Parenteral Route, Pulmonary, Mucosal, Oral Route, and Others. Based on Synthesis Technology, the market is segmented into Liquid Phase Peptide Synthesis (LPPS), Solid Phase Peptide Synthesis (SPPS), and Hybrid Technology. Based on Type of Manufacturers, the market is segmented into In-house and Outsourced. Based on Application, the market is segmented into Metabolic, Cardiovascular Disorder, GIT & Renal, Antiinfection & Dermatology, Respiratory, Central Nervous System, Cancer, Pain, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eli Lilly And Company, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Lonza Group AG, and Amgen, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Route of Administration
- Parenteral Route
- Oral Route
By Synthesis Technology
- Liquid Phase Peptide Synthesis (LPPS)
- Solid Phase Peptide Synthesis (SPPS)
- Hybrid Technology
By Type of Manufacturers
- Cardiovascular Disorder
- GIT & Renal
- Antiinfection & Dermatology
- Central Nervous System
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Eli Lilly And Company
- AstraZeneca PLC
- Teva Pharmaceuticals Industries Ltd.
- Novartis AG
- Pfizer, Inc.
- Sanofi S.A.
- GlaxoSmithKline PLC
- Takeda Pharmaceutical Company Limited
- Lonza Group AG
- Amgen, Inc.
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free